bismuth subnitrate + iodoform: clinical use

Prescribing considerations

• Confirm use is for a licensed ENT surgical cavity or acute epistaxis indication.
• Avoid placement into open wounds.
• Use caution in hyperthyroidism.
• Consider rare systemic toxicity with neurological or behavioural changes, particularly after extensive exposure; renal impairment was a possible predisposing factor in a published case.

Contraindications and cautions

• Known hypersensitivity to iodoform, iodine or bismuth.

Monitoring

• Observe for local hypersensitivity and new neurological symptoms while packing remains in place.
• If toxicity is suspected, arrange prompt clinical assessment and consider iodine, bismuth, renal, hepatic and thyroid investigations according to the presentation.

Clinical pharmacology

Iodoform releases iodine locally, producing antiseptic and anaesthetic effects; bismuth subnitrate is astringent and absorbent. Although product information describes no systemic absorption under expected use, rare case reports document systemic toxicity after extensive packing.

Formulation and product differences

• The product is ready-impregnated, X-ray-detectable ribbon gauze containing paste in liquid paraffin; purified water may also be present.
• It is supplied in a laminated pouch, requires refrigerated storage protected from light, and should not be used if the pouch is damaged.
• Unused gauze should be discarded after the procedure or session.